Choline magnesium trisalicylate

Identification

Name
Choline magnesium trisalicylate
Accession Number
DB01401
Type
Small Molecule
Groups
Approved
Description

Choline magnesium trisalicylate is a non-acetylated salicylate used widely as a nonsteroidal anti-inflammatory drug. Trisalicylate significantly reduces methotrexate renal clearance, displacing methotrexate from protein, increasing the fraction unbound by 28% [1, 2].

Structure
Thumb
Synonyms
Not Available
International/Other Brands
Tricosal / Trilisate
Categories
UNII
DJJ95FJP1H
CAS number
64425-90-7
Weight
Average: 539.814
Monoisotopic: 539.164188051
Chemical Formula
C26H29MgNO10
InChI Key
FQCQGOZEWWPOKI-UHFFFAOYSA-K
InChI
InChI=1S/3C7H6O3.C5H14NO.Mg/c3*8-6-4-2-1-3-5(6)7(9)10;1-6(2,3)4-5-7;/h3*1-4,8H,(H,9,10);7H,4-5H2,1-3H3;/q;;;+1;+2/p-3
IUPAC Name
magnesium(2+) ion (2-hydroxyethyl)trimethylazanium tris(2-hydroxybenzoate)
SMILES
[Mg++].C[N+](C)(C)CCO.OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O

Pharmacology

Indication

Choline magnesium trisalicylate is used to reduce pain and inflammation caused by conditions such as arthritis. This medication is also used to treat fever in adults.

Structured Indications
Not Available
Pharmacodynamics

Trisalicylate-choline is a non-steroidal anti-inflammatory drug (NSAID) that contains a combination of choline salicylate and magnesium salicylate. Does not affect platelet aggregation.

Mechanism of action

Inhibits prostaglandin synthesis; acts on the hypothalamus heat-regulating center to reduce fever; blocks the generation of pain impulses

TargetActionsOrganism
UProstaglandin G/H synthase 1
inhibitor
Human
UProstaglandin G/H synthase 2
inhibitor
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination

renal

Half life
Not Available
Clearance
Not Available
Toxicity

Salicylate intoxication, known as salicylism, may occur with large doses or extended therapy. Common symptoms of salicylism include headache, dizziness, tinnitus, hearing impairment, confusion, drowsiness, sweating, vomiting, diarrhea, and hyperventilation. A more severe degree of salicylate intoxication can lead to CNS disturbances, alteration in electrolyte balance, respiratory and metabolic acidosis, hyperthermia, and dehydration.

Affected organisms
Not Available
Pathways
PathwayCategory
Trisalicylate-choline Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with 19-norandrostenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with 5-androstenedione.Experimental, Illicit
AbciximabCholine magnesium trisalicylate may increase the anticoagulant activities of Abciximab.Approved
AcebutololCholine magnesium trisalicylate may decrease the antihypertensive activities of Acebutolol.Approved
AceclofenacThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Aceclofenac.Approved, Investigational
AcemetacinThe therapeutic efficacy of Acemetacin can be decreased when used in combination with Choline magnesium trisalicylate.Approved, Experimental, Investigational
AcenocoumarolCholine magnesium trisalicylate may increase the anticoagulant activities of Acenocoumarol.Approved
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Choline magnesium trisalicylate.Approved, Vet Approved
AclarubicinCholine magnesium trisalicylate may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Choline magnesium trisalicylate.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Alclofenac.Approved, Withdrawn
AlclometasoneThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Aldosterone.Experimental, Investigational
AldoxorubicinCholine magnesium trisalicylate may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level.Investigational
Alendronic acidThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Alendronic acid.Approved
AliskirenCholine magnesium trisalicylate may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlminoprofenThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Alminoprofen.Experimental
AlprenololCholine magnesium trisalicylate may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Choline magnesium trisalicylate.Approved, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Amcinonide.Approved
AmikacinCholine magnesium trisalicylate may decrease the excretion rate of Amikacin which could result in a higher serum level.Approved, Vet Approved
AmilorideCholine magnesium trisalicylate may decrease the antihypertensive activities of Amiloride.Approved
AmrubicinCholine magnesium trisalicylate may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
AncrodCholine magnesium trisalicylate may increase the anticoagulant activities of Ancrod.Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Andrographolide.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Androstenedione.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Anecortave.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with anecortave acetate.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Anisodamine.Investigational
AnnamycinCholine magnesium trisalicylate may decrease the excretion rate of Annamycin which could result in a higher serum level.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Antipyrine.Approved
Antithrombin III humanCholine magnesium trisalicylate may increase the anticoagulant activities of Antithrombin III human.Approved
ApixabanCholine magnesium trisalicylate may increase the anticoagulant activities of Apixaban.Approved
ApocyninThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Apocynin.Investigational
ApramycinCholine magnesium trisalicylate may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Apremilast.Approved, Investigational
ArbekacinCholine magnesium trisalicylate may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved, Investigational
ArdeparinCholine magnesium trisalicylate may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanCholine magnesium trisalicylate may increase the anticoagulant activities of Argatroban.Approved, Investigational
ArotinololCholine magnesium trisalicylate may decrease the antihypertensive activities of Arotinolol.Investigational
AtamestaneThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Atamestane.Investigational
AtenololCholine magnesium trisalicylate may decrease the antihypertensive activities of Atenolol.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Azapropazone.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Choline magnesium trisalicylate.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Choline magnesium trisalicylate.Approved
BalsalazideCholine magnesium trisalicylate may increase the nephrotoxic activities of Balsalazide.Approved, Investigational
BecaplerminCholine magnesium trisalicylate may increase the anticoagulant activities of Becaplermin.Approved, Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Beclomethasone dipropionate.Approved, Investigational
BefunololCholine magnesium trisalicylate may decrease the antihypertensive activities of Befunolol.Experimental
BekanamycinCholine magnesium trisalicylate may decrease the excretion rate of Bekanamycin which could result in a higher serum level.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Choline magnesium trisalicylate.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Bendazac.Experimental
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Choline magnesium trisalicylate.Approved
BenorilateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Benorilate.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Benoxaprofen.Withdrawn
BenzydamineThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Benzydamine.Approved
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with Choline magnesium trisalicylate.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Betamethasone.Approved, Vet Approved
BetaxololCholine magnesium trisalicylate may decrease the antihypertensive activities of Betaxolol.Approved
BetrixabanThe risk or severity of bleeding can be increased when Betrixaban is combined with Choline magnesium trisalicylate.Approved, Investigational
BevantololCholine magnesium trisalicylate may decrease the antihypertensive activities of Bevantolol.Approved
BevoniumThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Bevonium.Experimental
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Choline magnesium trisalicylate.Approved, Investigational
BisoprololCholine magnesium trisalicylate may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinCholine magnesium trisalicylate may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BopindololCholine magnesium trisalicylate may decrease the antihypertensive activities of Bopindolol.Approved
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Choline magnesium trisalicylate.Approved
BucillamineThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Bucillamine.Investigational
BucindololCholine magnesium trisalicylate may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Budesonide.Approved
BufexamacThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Bufexamac.Experimental
BufuralolCholine magnesium trisalicylate may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumadizoneThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Bumadizone.Experimental
BumetanideCholine magnesium trisalicylate may decrease the diuretic activities of Bumetanide.Approved
BupranololCholine magnesium trisalicylate may decrease the antihypertensive activities of Bupranolol.Approved
Calcium carbimideThe risk or severity of adverse effects can be increased when Calcium carbimide is combined with Choline magnesium trisalicylate.Withdrawn
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Choline magnesium trisalicylate.Experimental
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Choline magnesium trisalicylate.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Choline magnesium trisalicylate.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Choline magnesium trisalicylate.Approved
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Carbaspirin calcium.Experimental, Investigational
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Choline magnesium trisalicylate.Approved
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Choline magnesium trisalicylate.Approved, Vet Approved, Withdrawn
CarteololCholine magnesium trisalicylate may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolCholine magnesium trisalicylate may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Castanospermine.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Choline magnesium trisalicylate.Approved, Investigational
CeliprololCholine magnesium trisalicylate may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CertoparinCholine magnesium trisalicylate may increase the anticoagulant activities of Certoparin.Approved, Investigational
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Choline magnesium trisalicylate.Approved, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Choline magnesium trisalicylate.Approved, Vet Approved
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Choline magnesium trisalicylate.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Choline magnesium trisalicylate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Choline magnesium trisalicylate.Approved
CinoxacinCholine magnesium trisalicylate may increase the neuroexcitatory activities of Cinoxacin.Approved, Investigational, Withdrawn
Citric AcidCholine magnesium trisalicylate may increase the anticoagulant activities of Citric Acid.Approved, Nutraceutical, Vet Approved
ClobetasolThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Clobetasol.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Clobetasol propionate.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Clobetasone.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Clocortolone.Approved
Clodronic AcidThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Clodronic Acid.Approved, Investigational, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Clonixin.Approved
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Choline magnesium trisalicylate.Vet Approved
CloranololCholine magnesium trisalicylate may decrease the antihypertensive activities of Cloranolol.Experimental
ColesevelamColesevelam can cause a decrease in the absorption of Choline magnesium trisalicylate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Choline magnesium trisalicylate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Cortexolone 17α-propionate.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Corticosterone.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Cortisone acetate.Approved
CurcuminThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Curcumin.Investigational
CyclopenthiazideThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Choline magnesium trisalicylate.Experimental
CyclosporineCholine magnesium trisalicylate may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
Dabigatran etexilateCholine magnesium trisalicylate may increase the anticoagulant activities of Dabigatran etexilate.Approved
DalteparinCholine magnesium trisalicylate may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidCholine magnesium trisalicylate may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DarexabanCholine magnesium trisalicylate may increase the anticoagulant activities of Darexaban.Investigational
DaunorubicinCholine magnesium trisalicylate may decrease the excretion rate of Daunorubicin which could result in a higher serum level.Approved
DeferasiroxThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Deferasirox.Approved, Investigational
DeflazacortThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Deflazacort.Approved, Investigational
DelaprilThe risk or severity of adverse effects can be increased when Delapril is combined with Choline magnesium trisalicylate.Experimental
DesirudinCholine magnesium trisalicylate may increase the anticoagulant activities of Desirudin.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Desmopressin.Approved
DesonideThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Desonide.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Dexamethasone isonicotinate.Vet Approved
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Choline magnesium trisalicylate.Approved, Investigational
DextranCholine magnesium trisalicylate may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Choline magnesium trisalicylate may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Choline magnesium trisalicylate may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Choline magnesium trisalicylate may increase the anticoagulant activities of Dextran 75.Approved
DibekacinCholine magnesium trisalicylate may decrease the excretion rate of Dibekacin which could result in a higher serum level.Experimental
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Choline magnesium trisalicylate.Approved, Vet Approved
DicoumarolCholine magnesium trisalicylate may increase the anticoagulant activities of Dicoumarol.Approved
DifenpiramideThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Difenpiramide.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Choline magnesium trisalicylate.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Difluocortolone.Approved, Investigational, Withdrawn
DifluprednateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Difluprednate.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Choline magnesium trisalicylate.Approved
DihydrostreptomycinCholine magnesium trisalicylate may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Investigational, Vet Approved
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Choline magnesium trisalicylate.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Choline magnesium trisalicylate.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Choline magnesium trisalicylate.Approved
DoxorubicinCholine magnesium trisalicylate may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved, Investigational
DrospirenoneCholine magnesium trisalicylate may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Droxicam.Withdrawn
DuvelisibThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Duvelisib.Investigational
E-6201The risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with E-6201.Investigational
Edetic AcidCholine magnesium trisalicylate may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanCholine magnesium trisalicylate may increase the anticoagulant activities of Edoxaban.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Choline magnesium trisalicylate.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Choline magnesium trisalicylate.Approved
EnoxacinCholine magnesium trisalicylate may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational
EnoxaparinCholine magnesium trisalicylate may increase the anticoagulant activities of Enoxaparin.Approved
EnprostilThe therapeutic efficacy of Enprostil can be decreased when used in combination with Choline magnesium trisalicylate.Experimental
EpanololCholine magnesium trisalicylate may decrease the antihypertensive activities of Epanolol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Epirizole.Approved
EpirubicinCholine magnesium trisalicylate may decrease the excretion rate of Epirubicin which could result in a higher serum level.Approved
EplerenoneCholine magnesium trisalicylate may decrease the antihypertensive activities of Eplerenone.Approved
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Choline magnesium trisalicylate.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Choline magnesium trisalicylate.Approved
EquileninThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Equilin.Approved
EsmololCholine magnesium trisalicylate may decrease the antihypertensive activities of Esmolol.Approved
EstroneThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Estrone sulfate.Approved
Etacrynic acidCholine magnesium trisalicylate may decrease the diuretic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Choline magnesium trisalicylate.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Ethenzamide.Experimental
Ethyl biscoumacetateCholine magnesium trisalicylate may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Etidronic acid.Approved
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Choline magnesium trisalicylate.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Etofenamate.Approved, Investigational
EtoricoxibThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Etoricoxib.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Evening primrose oil.Approved, Investigational
ExisulindThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Exisulind.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Felbinac.Experimental
FenbufenThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Fenbufen.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Choline magnesium trisalicylate.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Choline magnesium trisalicylate.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Fentiazac.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Feprazone.Experimental
Ferulic acidCholine magnesium trisalicylate may increase the anticoagulant activities of Ferulic acid.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Choline magnesium trisalicylate.Approved, Investigational
FleroxacinCholine magnesium trisalicylate may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Choline magnesium trisalicylate.Approved, Withdrawn
FluasteroneThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Fluasterone.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Fludrocortisone.Approved
FluindioneCholine magnesium trisalicylate may increase the anticoagulant activities of Fluindione.Investigational
FlumequineCholine magnesium trisalicylate may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Flunisolide.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Flunixin.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Flunoxaprofen.Experimental
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Fluorometholone.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Choline magnesium trisalicylate.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Choline magnesium trisalicylate.Approved, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Fluticasone furoate.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Fluticasone propionate.Approved
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Choline magnesium trisalicylate.Approved, Nutraceutical, Vet Approved
FondaparinuxCholine magnesium trisalicylate may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumCholine magnesium trisalicylate may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Choline magnesium trisalicylate.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Formestane.Approved, Investigational, Withdrawn
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Choline magnesium trisalicylate.Approved
FramycetinCholine magnesium trisalicylate may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemideCholine magnesium trisalicylate may decrease the diuretic activities of Furosemide.Approved, Vet Approved
GabexateCholine magnesium trisalicylate may increase the anticoagulant activities of Gabexate.Investigational
GarenoxacinCholine magnesium trisalicylate may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinCholine magnesium trisalicylate may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Choline magnesium trisalicylate.Approved, Withdrawn
GemifloxacinCholine magnesium trisalicylate may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinCholine magnesium trisalicylate may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GentamicinCholine magnesium trisalicylate may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1ACholine magnesium trisalicylate may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GPX-150Choline magnesium trisalicylate may decrease the excretion rate of GPX-150 which could result in a higher serum level.Investigational
GrepafloxacinCholine magnesium trisalicylate may increase the neuroexcitatory activities of Grepafloxacin.Investigational, Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Guacetisal.Experimental
HalcinonideThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Halcinonide.Approved, Investigational, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with HE3286.Investigational
HeparinCholine magnesium trisalicylate may increase the anticoagulant activities of Heparin.Approved, Investigational
HigenamineThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Higenamine.Investigational
HydralazineCholine magnesium trisalicylate may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Choline magnesium trisalicylate.Approved, Vet Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Choline magnesium trisalicylate.Approved, Investigational
Hygromycin BCholine magnesium trisalicylate may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Ibandronate.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Choline magnesium trisalicylate.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Ibuproxam.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Icatibant.Approved
IdarubicinCholine magnesium trisalicylate may decrease the excretion rate of Idarubicin which could result in a higher serum level.Approved
IdraparinuxCholine magnesium trisalicylate may increase the anticoagulant activities of Idraparinux.Investigational
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Choline magnesium trisalicylate.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Choline magnesium trisalicylate.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Imidazole salicylate.Experimental
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Choline magnesium trisalicylate.Approved
IndenololCholine magnesium trisalicylate may decrease the antihypertensive activities of Indenolol.Withdrawn
IndobufenThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Indobufen.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Choline magnesium trisalicylate.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Indoprofen.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Choline magnesium trisalicylate.Approved, Investigational
IsepamicinCholine magnesium trisalicylate may decrease the excretion rate of Isepamicin which could result in a higher serum level.Experimental
IsoxicamThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Isoxicam.Withdrawn
IstaroximeThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Istaroxime.Investigational
KanamycinCholine magnesium trisalicylate may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Investigational, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Kebuzone.Experimental
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Choline magnesium trisalicylate.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Choline magnesium trisalicylate.Approved
LabetalolCholine magnesium trisalicylate may decrease the antihypertensive activities of Labetalol.Approved
LacidipineCholine magnesium trisalicylate may increase the hypotensive activities of Lacidipine.Approved, Investigational
LandiololCholine magnesium trisalicylate may decrease the antihypertensive activities of Landiolol.Investigational
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Choline magnesium trisalicylate.Approved, Investigational
Latanoprostene BunodThe therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Choline magnesium trisalicylate.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Choline magnesium trisalicylate.Approved, Investigational
LepirudinCholine magnesium trisalicylate may increase the anticoagulant activities of Lepirudin.Approved
LetaxabanCholine magnesium trisalicylate may increase the anticoagulant activities of Letaxaban.Investigational
LevobunololCholine magnesium trisalicylate may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinCholine magnesium trisalicylate may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Choline magnesium trisalicylate.Approved, Investigational
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Choline magnesium trisalicylate.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Lisofylline.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Choline magnesium trisalicylate.Approved
LonazolacThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Lonazolac.Experimental
LornoxicamThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Lornoxicam.Approved, Investigational
LorpiprazoleThe therapeutic efficacy of Choline magnesium trisalicylate can be increased when used in combination with Lorpiprazole.Approved
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Choline magnesium trisalicylate.Approved
LoteprednolThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Loteprednol.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Loxoprofen.Approved, Investigational
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Choline magnesium trisalicylate.Approved, Investigational
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Choline magnesium trisalicylate.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Choline magnesium trisalicylate.Vet Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Choline magnesium trisalicylate.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Choline magnesium trisalicylate.Approved, Investigational
ME-609The risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with ME-609.Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Choline magnesium trisalicylate.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Choline magnesium trisalicylate.Approved
MelagatranCholine magnesium trisalicylate may increase the anticoagulant activities of Melagatran.Experimental
MelengestrolThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Choline magnesium trisalicylate.Approved, Vet Approved
MepindololCholine magnesium trisalicylate may decrease the antihypertensive activities of Mepindolol.Experimental
MesalazineCholine magnesium trisalicylate may increase the nephrotoxic activities of Mesalazine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Metamizole.Investigational, Withdrawn
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Choline magnesium trisalicylate.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Choline magnesium trisalicylate.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Methylprednisolone.Approved, Vet Approved
MetipranololCholine magnesium trisalicylate may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Choline magnesium trisalicylate.Approved
MetoprololCholine magnesium trisalicylate may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MetrizamideCholine magnesium trisalicylate may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
MicronomicinCholine magnesium trisalicylate may decrease the excretion rate of Micronomicin which could result in a higher serum level.Experimental
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Choline magnesium trisalicylate.Approved
MizoribineThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Mizoribine.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Choline magnesium trisalicylate.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Mofebutazone.Experimental
MometasoneThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Mometasone.Approved, Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Choline magnesium trisalicylate.Approved
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Choline magnesium trisalicylate.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Choline magnesium trisalicylate.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Choline magnesium trisalicylate.Approved
NadololCholine magnesium trisalicylate may decrease the antihypertensive activities of Nadolol.Approved
NadroparinCholine magnesium trisalicylate may increase the anticoagulant activities of Nadroparin.Approved
NafamostatCholine magnesium trisalicylate may increase the anticoagulant activities of Nafamostat.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Choline magnesium trisalicylate.Approved
Nalidixic AcidCholine magnesium trisalicylate may increase the neuroexcitatory activities of Nalidixic Acid.Approved, Investigational
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Choline magnesium trisalicylate.Approved, Vet Approved
NCX 1022The risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with NCX 1022.Investigational
NeamineCholine magnesium trisalicylate may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NebivololCholine magnesium trisalicylate may decrease the antihypertensive activities of Nebivolol.Approved, Investigational
NemonoxacinCholine magnesium trisalicylate may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinCholine magnesium trisalicylate may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Choline magnesium trisalicylate.Approved
NetilmicinCholine magnesium trisalicylate may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Investigational
NifenazoneThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Nifenazone.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Niflumic Acid.Approved
NimesulideThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Nimesulide.Approved, Investigational, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Nitroaspirin.Investigational
NorfloxacinCholine magnesium trisalicylate may increase the neuroexcitatory activities of Norfloxacin.Approved
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Oleoyl-estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Choline magnesium trisalicylate.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Choline magnesium trisalicylate.Approved
OlsalazineCholine magnesium trisalicylate may increase the nephrotoxic activities of Olsalazine.Approved
Omacetaxine mepesuccinateThe risk or severity of can be d when Choline magnesium trisalicylate is combined with Omacetaxine mepesuccinate.Approved
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Choline magnesium trisalicylate.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Orgotein.Vet Approved
OtamixabanCholine magnesium trisalicylate may increase the anticoagulant activities of Otamixaban.Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Choline magnesium trisalicylate.Approved
Oxolinic acidCholine magnesium trisalicylate may increase the neuroexcitatory activities of Oxolinic acid.Experimental
OxprenololCholine magnesium trisalicylate may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Oxyphenbutazone.Approved, Withdrawn
PamidronateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Pamidronate.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Parecoxib.Approved
ParomomycinCholine magnesium trisalicylate may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
ParthenolideThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Parthenolide.Investigational
PazufloxacinCholine magnesium trisalicylate may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinCholine magnesium trisalicylate may increase the neuroexcitatory activities of Pefloxacin.Approved
PenbutololCholine magnesium trisalicylate may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
Pentaerythritol TetranitrateCholine magnesium trisalicylate may increase the anticoagulant activities of Pentaerythritol Tetranitrate.Approved
Pentosan PolysulfateCholine magnesium trisalicylate may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Choline magnesium trisalicylate.Approved
PhenindioneCholine magnesium trisalicylate may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenprocoumonCholine magnesium trisalicylate may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Choline magnesium trisalicylate.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Choline magnesium trisalicylate.Approved, Investigational
PindololCholine magnesium trisalicylate may decrease the antihypertensive activities of Pindolol.Approved
Pipemidic acidCholine magnesium trisalicylate may increase the neuroexcitatory activities of Pipemidic acid.Experimental
PirarubicinCholine magnesium trisalicylate may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
PiretanideCholine magnesium trisalicylate may decrease the diuretic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Pirfenidone.Approved, Investigational
Piromidic acidCholine magnesium trisalicylate may increase the neuroexcitatory activities of Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Choline magnesium trisalicylate.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Pirprofen.Experimental
Platelet Activating FactorCholine magnesium trisalicylate may decrease the antihypertensive activities of Platelet Activating Factor.Experimental
PlazomicinCholine magnesium trisalicylate may decrease the excretion rate of Plazomicin which could result in a higher serum level.Investigational
PlicamycinCholine magnesium trisalicylate may decrease the excretion rate of Plicamycin which could result in a higher serum level.Approved, Investigational, Withdrawn
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Choline magnesium trisalicylate.Approved
PractololCholine magnesium trisalicylate may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Choline magnesium trisalicylate.Approved
PranoprofenThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Pranoprofen.Experimental, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Prasterone.Approved, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Prasterone sulfate.Investigational
PrednicarbateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Prednicarbate.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Pregnenolone.Experimental, Investigational
ProbenecidThe serum concentration of Choline magnesium trisalicylate can be increased when it is combined with Probenecid.Approved
ProglumetacinThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Proglumetacin.Experimental
PropacetamolThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Propacetamol.Approved, Investigational
PropranololCholine magnesium trisalicylate may decrease the antihypertensive activities of Propranolol.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Propyphenazone.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Proquazone.Experimental
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Choline magnesium trisalicylate.Experimental
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Choline magnesium trisalicylate.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Choline magnesium trisalicylate.Vet Approved
Protein CCholine magnesium trisalicylate may increase the anticoagulant activities of Protein C.Approved
Protein S humanCholine magnesium trisalicylate may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeCholine magnesium trisalicylate may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrulifloxacinCholine magnesium trisalicylate may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with PTC299.Investigational
PuromycinCholine magnesium trisalicylate may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Choline magnesium trisalicylate.Approved, Investigational
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Choline magnesium trisalicylate.Approved
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Choline magnesium trisalicylate.Approved
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Choline magnesium trisalicylate.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Resveratrol.Approved, Experimental, Investigational
ReviparinCholine magnesium trisalicylate may increase the anticoagulant activities of Reviparin.Approved, Investigational
RibostamycinCholine magnesium trisalicylate may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Investigational
RimexoloneThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Rimexolone.Approved
RisedronateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Risedronate.Approved, Investigational
RivaroxabanCholine magnesium trisalicylate may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Choline magnesium trisalicylate.Investigational, Withdrawn
RosoxacinCholine magnesium trisalicylate may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational
RufloxacinCholine magnesium trisalicylate may increase the neuroexcitatory activities of Rufloxacin.Experimental
SabarubicinCholine magnesium trisalicylate may decrease the excretion rate of Sabarubicin which could result in a higher serum level.Investigational
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Choline magnesium trisalicylate.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Salicylamide.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Choline magnesium trisalicylate.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Choline magnesium trisalicylate.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Choline magnesium trisalicylate.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Choline magnesium trisalicylate.Investigational
SarilumabSarilumab may increase the immunosuppressive activities of Choline magnesium trisalicylate.Approved
SemapimodThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Semapimod.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Seratrodast.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Serrapeptase.Investigational
SisomicinCholine magnesium trisalicylate may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SitafloxacinCholine magnesium trisalicylate may increase the neuroexcitatory activities of Sitafloxacin.Experimental, Investigational
Sodium phosphateSodium phosphate may increase the nephrotoxic activities of Choline magnesium trisalicylate.Approved
SotalolCholine magnesium trisalicylate may decrease the antihypertensive activities of Sotalol.Approved
SP1049CCholine magnesium trisalicylate may decrease the excretion rate of SP1049C which could result in a higher serum level.Investigational
SparfloxacinCholine magnesium trisalicylate may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
SpectinomycinCholine magnesium trisalicylate may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Investigational, Vet Approved
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Choline magnesium trisalicylate.Approved
SRT501The risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with SRT501.Investigational
StreptomycinCholine magnesium trisalicylate may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
StreptozocinCholine magnesium trisalicylate may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Choline magnesium trisalicylate.Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Choline magnesium trisalicylate.Approved
SulodexideCholine magnesium trisalicylate may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Choline magnesium trisalicylate.Investigational
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Choline magnesium trisalicylate.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Suxibuzone.Experimental
TacrolimusCholine magnesium trisalicylate may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Choline magnesium trisalicylate.Approved
TalinololCholine magnesium trisalicylate may decrease the antihypertensive activities of Talinolol.Investigational
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Choline magnesium trisalicylate.Approved
TarenflurbilThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Tarenflurbil.Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Choline magnesium trisalicylate.Approved
Technetium Tc-99m etidronateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Technetium Tc-99m etidronate.Approved
Technetium Tc-99m medronateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Technetium Tc-99m medronate.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Choline magnesium trisalicylate.Approved, Investigational
TemafloxacinCholine magnesium trisalicylate may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Choline magnesium trisalicylate.Experimental, Investigational
TenidapThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Tenidap.Experimental
Tenofovir disoproxilThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Tenofovir disoproxil.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Choline magnesium trisalicylate.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Tepoxalin.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Teriflunomide.Approved
TertatololCholine magnesium trisalicylate may decrease the antihypertensive activities of Tertatolol.Experimental
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Tiaprofenic acid.Approved
Tiludronic acidThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Tiludronic acid.Approved, Investigational, Vet Approved
TimololCholine magnesium trisalicylate may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Tinoridine.Investigational
TixocortolThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Tixocortol.Approved, Withdrawn
TobramycinCholine magnesium trisalicylate may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Tolfenamic Acid.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Choline magnesium trisalicylate.Approved
TorasemideCholine magnesium trisalicylate may decrease the diuretic activities of Torasemide.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Choline magnesium trisalicylate.Approved
TranilastThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Tranilast.Approved, Investigational
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Choline magnesium trisalicylate.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Choline magnesium trisalicylate.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Triamcinolone.Approved, Vet Approved
TriamtereneCholine magnesium trisalicylate may decrease the antihypertensive activities of Triamterene.Approved
TribenosideThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Tribenoside.Experimental
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Choline magnesium trisalicylate.Approved, Vet Approved
TriptolideThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Triptolide.Investigational
TrovafloxacinCholine magnesium trisalicylate may increase the neuroexcitatory activities of Trovafloxacin.Approved, Investigational, Withdrawn
TroxerutinCholine magnesium trisalicylate may increase the anticoagulant activities of Troxerutin.Investigational
UlobetasolThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Ulobetasol.Approved
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Choline magnesium trisalicylate.Approved, Investigational
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Choline magnesium trisalicylate.Investigational, Withdrawn
ValrubicinCholine magnesium trisalicylate may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Choline magnesium trisalicylate.Approved, Investigational
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Choline magnesium trisalicylate.Approved
WarfarinCholine magnesium trisalicylate may increase the anticoagulant activities of Warfarin.Approved
XimelagatranCholine magnesium trisalicylate may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
ZaltoprofenThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Zaltoprofen.Approved, Investigational
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Choline magnesium trisalicylate.Approved, Investigational, Withdrawn
ZofenoprilThe risk or severity of adverse effects can be increased when Zofenopril is combined with Choline magnesium trisalicylate.Experimental
Zoledronic acidThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Zoledronic acid.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Zomepirac.Withdrawn
Zoptarelin doxorubicinCholine magnesium trisalicylate may decrease the excretion rate of Zoptarelin doxorubicin which could result in a higher serum level.Investigational
ZorubicinCholine magnesium trisalicylate may decrease the excretion rate of Zorubicin which could result in a higher serum level.Experimental
Food Interactions
Not Available

References

General References
  1. Nadkarni MM, Peller CA, Retig J: Eosinophilic hepatitis after ingestion of choline magnesium trisalicylate. Am J Gastroenterol. 1992 Jan;87(1):151-3. [PubMed:1728115]
  2. Tracy TS, Krohn K, Jones DR, Bradley JD, Hall SD, Brater DC: The effects of a salicylate, ibuprofen, and naproxen on the disposition of methotrexate in patients with rheumatoid arthritis. Eur J Clin Pharmacol. 1992;42(2):121-5. [PubMed:1618240]
External Links
Human Metabolome Database
HMDB15473
PubChem Compound
54682045
PubChem Substance
46505243
ChemSpider
10642393
PharmGKB
PA164749164

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Dosage forms
Not Available
Prices
Unit descriptionCostUnit
Choline mag trisal 1 gm tablet1.23USD tablet
Choline mag trisal 750 mg tablet0.81USD tablet
Choline mag trisal 500 mg tablet0.57USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
logP1.98ChemAxon
pKa (Strongest Acidic)2.79ChemAxon
pKa (Strongest Basic)-6.3ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area60.36 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity46.13 m3·mol-1ChemAxon
Polarizability12.38 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.9852
Blood Brain Barrier-0.8993
Caco-2 permeable+0.5436
P-glycoprotein substrateSubstrate0.7681
P-glycoprotein inhibitor INon-inhibitor0.9522
P-glycoprotein inhibitor IINon-inhibitor0.6479
Renal organic cation transporterNon-inhibitor0.7147
CYP450 2C9 substrateNon-substrate0.7398
CYP450 2D6 substrateNon-substrate0.7764
CYP450 3A4 substrateSubstrate0.588
CYP450 1A2 substrateNon-inhibitor0.7658
CYP450 2C9 inhibitorNon-inhibitor0.8703
CYP450 2D6 inhibitorNon-inhibitor0.7642
CYP450 2C19 inhibitorNon-inhibitor0.8941
CYP450 3A4 inhibitorNon-inhibitor0.9072
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9752
Ames testNon AMES toxic0.7389
CarcinogenicityNon-carcinogens0.729
BiodegradationReady biodegradable0.5807
Rat acute toxicity2.3576 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8568
hERG inhibition (predictor II)Non-inhibitor0.7428
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as salicylic acids. These are ortho-hydroxylated benzoic acids.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Benzoic acids and derivatives
Direct Parent
Salicylic acids
Alternative Parents
Benzoic acids / Benzoyl derivatives / Phenoxides / 1-hydroxy-2-unsubstituted benzenoids / 1-hydroxy-4-unsubstituted benzenoids / Cholines / Vinylogous acids / Tetraalkylammonium salts / 1,2-aminoalcohols / Carboxylic acid salts
show 7 more
Substituents
Salicylic acid / Benzoic acid / Benzoyl / 1-hydroxy-4-unsubstituted benzenoid / 1-hydroxy-2-unsubstituted benzenoid / Choline / Phenol / Phenoxide / Tetraalkylammonium salt / Vinylogous acid
show 19 more
Molecular Framework
Not Available
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gas...
Gene Name
PTGS1
Uniprot ID
P23219
Uniprot Name
Prostaglandin G/H synthase 1
Molecular Weight
68685.82 Da
References
  1. Nizankowska E, Dworski R, Soja J, Szczeklik A: Salicylate pre-treatment attenuates intensity of bronchial and nasal symptoms precipitated by aspirin in aspirin-intolerant patients. Clin Exp Allergy. 1990 Nov;20(6):647-52. [PubMed:2083404]
  2. Simon RA: Adverse respiratory reactions to aspirin and nonsteroidal anti-inflammatory drugs. Curr Allergy Asthma Rep. 2004 Jan;4(1):17-24. [PubMed:14680616]
  3. Schwartz KA: Aspirin resistance: a review of diagnostic methodology, mechanisms, and clinical utility. Adv Clin Chem. 2006;42:81-110. [PubMed:17131625]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and...
Gene Name
PTGS2
Uniprot ID
P35354
Uniprot Name
Prostaglandin G/H synthase 2
Molecular Weight
68995.625 Da
References
  1. Simon RA: Adverse respiratory reactions to aspirin and nonsteroidal anti-inflammatory drugs. Curr Allergy Asthma Rep. 2004 Jan;4(1):17-24. [PubMed:14680616]
  2. Brzozowski T, Konturek PC, Sliwowski Z, Kwiecien S, Drozdowicz D, Pawlik M, Mach K, Konturek SJ, Pawlik WW: Interaction of nonsteroidal anti-inflammatory drugs (NSAID) with Helicobacter pylori in the stomach of humans and experimental animals. J Physiol Pharmacol. 2006 Sep;57 Suppl 3:67-79. [PubMed:17033106]
  3. Wang HJ, Liu XJ, Yang KX, Luo FM, Lou JY, Peng ZL: [Effects of nonsteroidal anti-inflammatory drug celecoxib on expression of cyclooxygenase-2 (COX-2) in ovarian carcinoma cell]. Sichuan Da Xue Xue Bao Yi Xue Ban. 2006 Sep;37(5):757-60. [PubMed:17037745]
  4. Shen J, Gammon MD, Terry MB, Teitelbaum SL, Neugut AI, Santella RM: Genetic polymorphisms in the cyclooxygenase-2 gene, use of nonsteroidal anti-inflammatory drugs, and breast cancer risk. Breast Cancer Res. 2006;8(6):R71. [PubMed:17181859]
  5. Nakano M, Denda N, Matsumoto M, Kawamura M, Kawakubo Y, Hatanaka K, Hiramoto Y, Sato Y, Noshiro M, Harada Y: Interaction between cyclooxygenase (COX)-1- and COX-2-products modulates COX-2 expression in the late phase of acute inflammation. Eur J Pharmacol. 2007 Mar 22;559(2-3):210-8. Epub 2006 Dec 16. [PubMed:17258197]

Drug created on July 08, 2007 11:07 / Updated on November 09, 2017 02:59